Operator
Good morning, my name is Laurie, and I ll be your conference operator today. At this time, I would like to welcome everyone to the Viatris First Quarter 2021 Earnings Call and Webcast. [Operator Instructions] Thank you. I will now turn the call over to Melissa Trombetta, Head of Global Investor Relations. Please go ahead.
Melissa Trombetta
Head of Global Investor Relations
Thank you, Laurie. Good morning, everyone. Welcome to Viatris s first quarter 2021 earnings conference call. Joining me on this call are Viatris s Chief Executive Officer, Michael Goettler; President, Rajiv Malik; Chief Financial Officer, Sanjeev Narula; Chief Accounting Officer and Controller, Paul Campbell; and Bill Szablewski, Head of Capital Markets. While some of us are in remote locations, I would ask for your patience, should we encounter any technical difficulties.
Ghaziabad Oxygen Crisis: Oxygen Shortage Continues In Ghaziabad - गाजियाबाद ऑक्सीजन संकट: बरकरार है किल्लत, ऑक्सिजन के लिए 48 घंटे तक की वेटिंग
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Lodestar UM Studios takes Hello Charlie on a trip in the Mahindra FURIO
adgully.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adgully.com Daily Mail and Mail on Sunday newspapers.
News | March 8, 2021
Viatris Inc. And Kindeva Drug Delivery Announce FDA Tentative Approval Of The First Abbreviated New Drug Application Generic Version Of Symbicort® (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol
Source: Kindeva Drug Delivery
Milestone reinforces Viatris commitment to complex products and innovative solutions to help increase patient access
PITTSBURGH and ST. PAUL, Minn., March 8, 2021 Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort
®
based on an Abbreviated New Drug Application (ANDA). Symbicort is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD).